ChitogenX (CHNXF) CEO Phil Deschamps - C-Suite Interview Series

Recorded November 4, 2022. Noble Capital Markets Senior Research Analyst Gregory Aurand sits down with ChitogenX CEO Phil Deschamps for this exclusive interview. Topics covered include:

How the name change to ChitogenX better reflects the company’s values and core competencies

The strengths of the leadership team

What is chitosan? – what is the value add in utilizing it in soft tissue surgery?

Pre-clinical meniscal repair study – what data points can be expected?

What other market opportunities are on the horizon for the platform?

Investigating the market opportunity for developing their own medical grade chitosan

Research, News, and Market Data on ChitogenX: https://channelchek.com/company/chnxf

About ChitogenX

ChitogenX Inc. is a clinical stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various Regenerative Medicine Applications. Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease. Further information about ChitogenX is available on the Company's website at www.chitogenx.com and on SEDAR at www.sedar.com.